These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25125683)

  • 1. Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment.
    Vail ME; Murone C; Tan A; Hii L; Abebe D; Janes PW; Lee FT; Baer M; Palath V; Bebbington C; Yarranton G; Llerena C; Garic S; Abramson D; Cartwright G; Scott AM; Lackmann M
    Cancer Res; 2014 Aug; 74(16):4470-81. PubMed ID: 25125683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: potential as EphA3-specific tumor-targeting reagents.
    Vearing C; Lee FT; Wimmer-Kleikamp S; Spirkoska V; To C; Stylianou C; Spanevello M; Brechbiel M; Boyd AW; Scott AM; Lackmann M
    Cancer Res; 2005 Aug; 65(15):6745-54. PubMed ID: 16061656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells.
    La Rocca F; Airoldi I; Di Carlo E; Marotta P; Falco G; Simeon V; Laurenzana I; Trino S; De Luca L; Todoerti K; Villani O; Lackmann M; D'Auria F; Frassoni F; Neri A; Del Vecchio L; Musto P; Cilloni D; Caivano A
    Cell Oncol (Dordr); 2017 Oct; 40(5):483-496. PubMed ID: 28721629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-controlled EphA3 marks a human endometrium-derived multipotent mesenchymal stromal cell that supports vascular growth.
    To C; Farnsworth RH; Vail ME; Chheang C; Gargett CE; Murone C; Llerena C; Major AT; Scott AM; Janes PW; Lackmann M
    PLoS One; 2014; 9(11):e112106. PubMed ID: 25420155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EphA3 contributes to tumor growth and angiogenesis in human gastric cancer cells.
    Lv XY; Wang J; Huang F; Wang P; Zhou JG; Wei B; Li SH
    Oncol Rep; 2018 Oct; 40(4):2408-2416. PubMed ID: 30066881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.
    Charmsaz S; Al-Ejeh F; Yeadon TM; Miller KJ; Smith FM; Stringer BW; Moore AS; Lee FT; Cooper LT; Stylianou C; Yarranton GT; Woronicz J; Scott AM; Lackmann M; Boyd AW
    Leukemia; 2017 Aug; 31(8):1779-1787. PubMed ID: 27922598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of cancer-associated EPHA3 mutations on lung cancer.
    Zhuang G; Song W; Amato K; Hwang Y; Lee K; Boothby M; Ye F; Guo Y; Shyr Y; Lin L; Carbone DP; Brantley-Sieders DM; Chen J
    J Natl Cancer Inst; 2012 Aug; 104(15):1182-97. PubMed ID: 22829656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme.
    Day BW; Stringer BW; Al-Ejeh F; Ting MJ; Wilson J; Ensbey KS; Jamieson PR; Bruce ZC; Lim YC; Offenhäuser C; Charmsaz S; Cooper LT; Ellacott JK; Harding A; Leveque L; Inglis P; Allan S; Walker DG; Lackmann M; Osborne G; Khanna KK; Reynolds BA; Lickliter JD; Boyd AW
    Cancer Cell; 2013 Feb; 23(2):238-48. PubMed ID: 23410976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The putative tumor suppressor gene EphA3 fails to demonstrate a crucial role in murine lung tumorigenesis or morphogenesis.
    Lahtela J; Pradhan B; Närhi K; Hemmes A; Särkioja M; Kovanen PE; Brown A; Verschuren EW
    Dis Model Mech; 2015 Apr; 8(4):393-401. PubMed ID: 25713296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of the role of tyrosine kinase receptor EPHA3 in colorectal cancer.
    Andretta E; Cartón-García F; Martínez-Barriocanal Á; de Marcondes PG; Jimenez-Flores LM; Macaya I; Bazzocco S; Bilic J; Rodrigues P; Nieto R; Landolfi S; Ramon Y Cajal S; Schwartz S; Brown A; Dopeso H; Arango D
    Sci Rep; 2017 Feb; 7():41576. PubMed ID: 28169277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EphA-Mediated Regulation of Stomatin Expression in Prostate Cancer Cells.
    Nishida M; Sato A; Shimizu A; Rahman NIA; Wada A; Kageyama S; Ogita H
    Cancer Med; 2024 Oct; 13(19):e70276. PubMed ID: 39377541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The EphA3 receptor is expressed in a subset of rhabdomyosarcoma cell lines and suppresses cell adhesion and migration.
    Clifford N; Smith LM; Powell J; Gattenlöhner S; Marx A; O'Connor R
    J Cell Biochem; 2008 Dec; 105(5):1250-9. PubMed ID: 18814179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of platelet-derived growth factor receptor α by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer.
    Laing N; McDermott B; Wen S; Yang D; Lawson D; Collins M; Reimer C; Hall PA; Andersén H; Snaith M; Wang X; Bedian V; Cao ZA; Blakey D
    Mol Pharmacol; 2013 Jun; 83(6):1247-56. PubMed ID: 23558446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical role of EphA3 in cancer and current state of EphA3 drug therapeutics.
    London M; Gallo E
    Mol Biol Rep; 2020 Jul; 47(7):5523-5533. PubMed ID: 32621117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms.
    Lisabeth EM; Fernandez C; Pasquale EB
    Biochemistry; 2012 Feb; 51(7):1464-75. PubMed ID: 22242939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells.
    Hsieh CL; Gardner TA; Miao L; Balian G; Chung LW
    Cancer Gene Ther; 2004 Feb; 11(2):148-55. PubMed ID: 14695756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3.
    Lahtela J; Corson LB; Hemmes A; Brauer MJ; Koopal S; Lee J; Hunsaker TL; Jackson PK; Verschuren EW
    Cell Cycle; 2013 Feb; 12(4):625-34. PubMed ID: 23324396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A critical role for the EphA3 receptor tyrosine kinase in heart development.
    Stephen LJ; Fawkes AL; Verhoeve A; Lemke G; Brown A
    Dev Biol; 2007 Feb; 302(1):66-79. PubMed ID: 17046737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
    Chung LW; Baseman A; Assikis V; Zhau HE
    J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EPHA3 as a novel therapeutic target in the hematological malignancies.
    Keane N; Freeman C; Swords R; Giles FJ
    Expert Rev Hematol; 2012 Jun; 5(3):325-40. PubMed ID: 22780212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.